A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

• Asthma
• Diabetes Mellitus

• Drug: Inhaled Insulin
  
  Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
• Drug: Subcutaneous Insulin
  
  Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.

• Experimental: Inhaled Insulin
  
  Intervention: Drug: Inhaled Insulin
• Active Comparator: Subcutaneous Insulin
  
  Intervention: Drug: Subcutaneous Insulin

Inclusion Criteria:

• Diabetes Mellitus (Type 1 or Type 2) currently controlled with injected insulin
• Mild intermittent or mild to moderate persistent asthma

Exclusion Criteria:

• Poorly controlled, unstable or steroid-dependent asthma, insulin pump therapy, smoking